Aerie Pharmaceuticals, Inc.
(NASDAQ : AERI)

( )
AERI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. -5.17%45.850.0%$310.78m
HZNPHorizon Therapeutics Plc -3.75%99.845.4%$183.34m
VRXValeant Pharmaceuticals International, Inc. 1.11%23.7214.1%$139.57m
CTLTCatalent, Inc. -4.16%122.342.0%$135.52m
ICLRICON plc -0.09%272.812.8%$113.95m
UTHRUnited Therapeutics Corp. -1.74%185.9913.9%$77.42m
JAZZJazz Pharmaceuticals Plc -1.99%120.262.1%$74.09m
BHCBausch Health Cos., Inc. 1.11%23.720.0%$61.74m
PRGOPerrigo Co. Plc -0.17%35.776.9%$60.39m
ARGXargenx SE -3.80%283.700.0%$54.64m
CPIXCumberland Pharmaceuticals, Inc. 8.77%4.590.6%$52.10m
ENDPEndo International Plc -5.49%4.998.5%$44.06m
IRWDIronwood Pharmaceuticals, Inc. -1.17%10.989.5%$26.09m
PCRXPacira Biosciences, Inc. -2.27%52.539.8%$24.74m
AXSMAxsome Therapeutics, Inc. -3.33%32.241.8%$22.87m

Company Profile

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.